文献速递头颈与中枢神经肿瘤

新诊断和复发IDH1/2野生型胶质母细胞瘤患者的可操作分子改变及治疗意义:基于广泛二代测序分析的大型单机构经验

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
PubMed 文献 · Eur J Cancer · 2023-06-22

该单机构回顾性研究利用FoundationOne®CDx对442例IDH1/2野生型胶质母细胞瘤样本行二代测序,98.2%获测序图谱。约半数患者存在至少一个可操作分子改变,但仅3.4%为ESCAT IB-IC类、6.7%为ESCAT IIB类;仅36例(10.5%)接受个性化治疗。达拉非尼/曲美替尼组疾病控制率77%、客观缓解率22%,中位无进展生存期5.2个月。作者认为二代测序应在临床试验背景下进行。

要点

  • 442例样本中98.2%获得二代测序图谱,中位测序时间距诊断7.4个月(IQR 3.4-13.2)。
  • 约半数患者有至少一个可操作改变,但仅3.4%为ESCAT IB-IC、6.7%为ESCAT IIB。
  • 仅36例(10.5%)接受个性化治疗;达拉非尼/曲美替尼组疾病控制率77%、客观缓解率22%。

核心结论

  • 本研究证明在胶质母细胞瘤样本中进行二代测序是可行的。
  • 由于临床相关靶点数量有限且仅小部分患者接受靶向治疗,二代测序检测应在临床试验背景下进行。
  • 结果支持抗BRAF/抗MEK的活性,其他药物需前瞻性研究结果才能得出可靠结论。

研究设计与样本

  • 单机构回顾性分析,使用FoundationOne®CDx对大型IDH1/2野生型胶质母细胞瘤队列进行二代测序。
  • 共442例样本,98.2%可获得二代测序图谱。
  • 目标为基于ESCAT可靶向性分类识别诊断和/或复发时的潜在可操作分子改变,并了解二代测序对靶向治疗可及性和活性的临床意义。

主要发现

  • 从诊断到二代测序分析的中位时间为7.4个月(四分位距3.4-13.2)。
  • 约半数患者有至少一个可操作分子改变,其中仅3.4%分类为ESCAT IB-IC,6.7%为ESCAT IIB。
  • 仅36例患者(10.5%)在临床试验中或作为超说明书/同情用药从二线(中位线数3)接受个性化治疗。
  • 大多数患者未接受靶向治疗,原因为临床恶化/死亡(49.6%)。
  • 接受达拉非尼/曲美替尼治疗的9例患者疾病控制率最高为77%,客观缓解率为22%,中位无进展生存期5.2个月;其他方案未见完全/部分缓解。

关键数值与推荐

  • ESCAT IB-IC类占3.4%,ESCAT IIB类占6.7%。
  • 达拉非尼/曲美替尼组(9例)疾病控制率77%、客观缓解率22%、中位无进展生存期5.2个月。
  • 抗BRAF/抗MEK组9例中4例(44.4%)无进展生存期比值>1.3;erdafitinib组4例中2例(50%)无进展生存期比值>1.3;capmatinib组1例中1例无进展生存期比值>1.3。
  • 携带ROS1-GOCP融合的复发胶质母细胞瘤患者接受entrectinib后完全缓解持续11.3个月。

临床怎么用

  • 作者认为二代测序检测应在临床试验背景下进行。
  • 作者认为结果支持抗BRAF/抗MEK的活性,其他药物需前瞻性研究结果才能得出可靠结论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Next-generation sequencing (NGS) panels enable the identification of alterations in cancer-related genes. This may guide a molecularly targeted strategy for the treatment of glioblastoma (GBM). MATERIAL AND METHODS: We retrospectively analysed data obtained using FoundationOne®CDx in a large cohort of IDH1/2 wild-type GBM. We aimed to 1) identify potentially actionable molecular alterations at diagnosis and/or recurrence based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) defined categories of targetability, 2) understand the clinical implications of NGS in terms of access to and activity of targeted therapies. RESULTS: In 442 samples, an NGS profile was available in 98.2%. The median time from diagnosis to NGS profiling was 7.4 months (interquartile range (IQR): 3.4-13.2). Although about half of the patients had at least one actionable molecular alteration, only 3.4% of them were classified as ESCAT IB-IC and 6.7% as ESCAT IIB. Only 36 patients (10.5%) received personalised treatment in clinical trials or as off-label/compassionate use from second-line (median line 3). Most patients did not receive targeted therapy due to clinical deterioration/death (49.6%). Patients treated with dabrafenib/trametinib (9 patients) had the highest disease control rate of 77% and an objective response rate of 22%, with a median progression-free survival (PFS) of 5.2 months. No complete/partial responses were seen with the other regimens. 4/9 (44.4%) patients on anti-BRAF/anti-MEK, 2/4 patients (50%) on erdafitinib and 1/1 patient on capmatinib had a PFS ratio > 1.3. One recurrent GBM patient with ROS1-GOCP fusion maintained a complete response for 11.3 months on entrectinib. CONCLUSIONS: Our study demonstrated the feasibility of NGS in GBM samples. As the number of clinically relevant targets was limited and only a small group of GBM patients were treated with targeted therapy, NGS testing should be performed in the context of clinical trials. Our results support the activity of anti-BRAF/anti-MEK, while for the other agents prospective study results are needed to draw solid conclusions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Padovan M, Maccari M, Bosio A, et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis. Eur J Cancer. 2023. PMID: 37481865. doi:10.1016/j.ejca.2023.112959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。